BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future . World J Clin Oncol 2021; 12(4): 217-237 [PMID: 33959476 DOI: 10.5306/wjco.v12.i4.217]
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/217.htm
Number Citing Articles
1
Akanksha Dessai, Usha Yogendra Nayak, Yogendra Nayak. Precision nanomedicine to treat non-small cell lung cancerLife Sciences 2024; 346: 122614 doi: 10.1016/j.lfs.2024.122614
2
Mervat Mahrous, Abdalla Omar Jebriel, Ahmed Allehebi, Amr Shafik, Fadi El Karak, Filippo Venturini, Hamed Alhusaini, Matthias Meergans, Mehmet Ali Nahit Sendur, Mohamed Ouda, Muath Al-Nassar, Saadettin Kilickap, Saeed Al Turki, Turki Al-Fayea, Yasser Abdel Kader. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and RussiaCureus 2023;  doi: 10.7759/cureus.41992
3
Ram Sharma, Esha Chatterjee, Jacob Mathew, Sachin Sharma, N. Vijayakameswara Rao, Chun-Hsu Pan, Sung-Bau Lee, Ashwani Dhingra, Ajmer S. Grewal, Jing Ping Liou, Santosh K. Guru, Kunal Nepali. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrierEuropean Journal of Medicinal Chemistry 2022; 240: 114602 doi: 10.1016/j.ejmech.2022.114602
4
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike. Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case ReportOncoTargets and Therapy 2023; : 465 doi: 10.2147/OTT.S404035
5
Tia Cheunkarndee, Matthew Z. Guo, Stefanie Houseknecht, Josephine L. Feliciano, Christine L. Hann, Vincent K. Lam, Benjamin P. Levy, Joseph C. Murray, Julie R. Brahmer, Patrick M. Forde, Kristen A. Marrone, Susan C. Scott. First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound MutationsJTO Clinical and Research Reports 2024; 5(6): 100686 doi: 10.1016/j.jtocrr.2024.100686
6
Marianne Davies. Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice NurseClinical Journal of Oncology Nursing 2022; 26(3): 245 doi: 10.1188/22.CJON.245-251
7
Anupa John, Vanita Noronha, Ajaykumar Singh, Nandini Menon, Kumar Prabhash. Amivantamab: A narrative drug reviewCancer Research, Statistics, and Treatment 2023; 6(2): 261 doi: 10.4103/crst.crst_166_23
8
Afshan Fathima Nawas, Ashley Solmonson, Boning Gao, Ralph J. DeBerardinis, John D. Minna, Maralice Conacci-Sorrell, Carole R. Mendelson. IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cellsCell Communication and Signaling 2023; 21(1) doi: 10.1186/s12964-023-01348-1
9
Danilo Rocco, Luigi Sapio, Luigi Della Gravara, Silvio Naviglio, Cesare Gridelli. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and HopesInternational Journal of Molecular Sciences 2023; 24(3): 2433 doi: 10.3390/ijms24032433
10
Eurydice Angeli, Guilhem Bousquet. Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain BarrierPharmaceutics 2021; 13(9): 1446 doi: 10.3390/pharmaceutics13091446
11
Jessica S. Donington, Barbara Gitlitz, Eric Lim, Isabelle Opitz, Young Tae Kim, Nasser Altorki. Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the SurgeonThe Annals of Thoracic Surgery 2023; 115(6): 1544 doi: 10.1016/j.athoracsur.2022.09.029
12
Moritz Kleemiss, Christa E. Müller, Marion Schneider, Rainer Strotmann, Katrin Orlowski, Kosalaram Goteti, Mert Yanik, Peter Brossart, Franz-Georg Bauernfeind. Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case ReportClinical Lung Cancer 2024;  doi: 10.1016/j.cllc.2024.05.008
13
Shreyas Bellur, Atulya Aman Khosla, Ahmad Ozair, Rupesh Kotecha, Michael W. McDermott, Manmeet S. Ahluwalia. Management of Brain Metastases: A Review of Novel TherapiesSeminars in Neurology 2023; 43(06): 845 doi: 10.1055/s-0043-1776782
14
Prerana Jha, Vaishakhi Trivedi, Ranendra Biswal, Pratik Chandrani, Venkataramanan Ramachandran, Minit Shah, Anuradha Choughule, Vanita Noronha, Kumar Prabhash, Prashant Kumar. Identification of a rare EGFR exon 18 mutation in lung adenocarcinoma using targeted next-generation sequencing as a tool for precision medicineCancer Research, Statistics, and Treatment 2023; 6(4): 589 doi: 10.4103/crst.crst_287_23
15
Dong Hoon Shin, Jeong Yeon Jo, Minyoung Choi, Kyung-Hee Kim, Young-Ki Bae, Sang Soo Kim. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerExperimental & Molecular Medicine 2023; 55(10): 2220 doi: 10.1038/s12276-023-01091-0
16
Trine V. Larsen, Christoffer T. Maansson, Tina F. Daugaard, Brage S. Andresen, Boe S. Sorensen, Anders L. Nielsen. Trans-Regulation of Alternative PD-L1 mRNA Processing by CDK12 in Non-Small-Cell Lung Cancer CellsCells 2023; 12(24): 2844 doi: 10.3390/cells12242844
17
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with ErlotinibClinical Cancer Investigation Journal 2022; 11(4): 5 doi: 10.51847/rvQeWyfFBI
18
Alissa J. Cooper, Lecia V. Sequist, Ted W. Johnson, Jessica J. Lin. LTK fusions: A new target emerges in non-small cell lung cancerCancer Cell 2022; 40(1): 23 doi: 10.1016/j.ccell.2021.12.012
19
K.K. Lactionov, E.V. Reutova, A.E. Gorokhov, A.M. Fedun, T.F. Ibragimov, D.L. Stroyakovski, G.B. Statsenko. Approaches to the diagnosis and treatment of patients with stage III—IV non-small cell lung cancer in Russia. Preliminary results of a prospective multicenter non-interventional observational study KARLOnkologiya. Zhurnal imeni P.A.Gertsena 2023; 12(6): 33 doi: 10.17116/onkolog20231206133
20
Christine M. Bestvina, Dexter Waters, Laura Morrison, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Andy He, Julie Vanderpoel. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancerJournal of Medical Economics 2024; 27(1): 292 doi: 10.1080/13696998.2024.2314430
21
Thomas Yang Sun, Millie Das. Lung CancerRespiratory Medicine 2023; : 165 doi: 10.1007/978-3-031-38412-7_8
22
Sethi Ashish, Robin R Rodriguez, Purva Sethi, Fang Yu, Moses Raj. Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell LymphomaCureus 2022;  doi: 10.7759/cureus.29922
23
Harsh Sahu. Amivantamab in non-small-cell lung cancerCancer Research, Statistics, and Treatment 2023; 6(3): 486 doi: 10.4103/crst.crst_261_23
24
Showkat Ahmad Mir, Prajna Paramita Mohanta, Rajesh Kumar Meher, Iswar baitharu, Mukesh Kumar Raval, Ajaya Kumar Behera, Binata Nayak. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and in-vitro studySaudi Journal of Biological Sciences 2022; 29(12): 103478 doi: 10.1016/j.sjbs.2022.103478
25
Ajaykumar Singh, Vijay Patil, Nandini Menon, Sucheta More, Srushti Jain, Supriya Goud, Darshit Shah, Minit Shah, Kunal Jobanputra, Ahmad Ubharay. Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight yearsCancer Research, Statistics, and Treatment 2024; 7(1): 19 doi: 10.4103/crst.crst_307_23
26
Navdeep Dehar, Tasnima Abedin, Patricia Tang, Gwyn Bebb, Winson Y. Cheung. A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology TestsCurrent Oncology 2022; 29(12): 9916 doi: 10.3390/curroncol29120780
27
Julien Mazieres, Helene Vioix, Boris M. Pfeiffer, Rhiannon I. Campden, Zhiyuan Chen, Bart Heeg, Alexis B. Cortot. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and OutcomesClinical Lung Cancer 2023; 24(6): 483 doi: 10.1016/j.cllc.2023.06.008
28
Da Som Jeon, Cheol‐kyu Park, Seung Joon Kim, Chan Kwon Park, Yoon Soo Chang, Chi Young Jung, Sung Yong Lee, Shin‐Yup Lee, Jeong‐Seon Ryu, Jeong Eun Lee, Kye Young Lee, Tae Won Jang, Seung Hun Jang, Seong Hoon Yoon, Sang Hoon Lee, Chang‐min Choi, Hyeong Ryul Kim, Yeon Joo Kim. Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South KoreaThoracic Cancer 2024; 15(6): 448 doi: 10.1111/1759-7714.15213
29
Bogdan Cosmin Tanase, Alin Ionut Burlacu, Claudiu Eduard Nistor, Teodor Horvat, Cristian Oancea, Monica Marc, Emanuela Tudorache, Tudor Mateescu, Diana Manolescu. A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer PatientsHealthcare 2023; 11(12): 1745 doi: 10.3390/healthcare11121745
30
Prerana Jha, Vaishakhi Trivedi, Pooja Mahesh Kulkarni, Simran Rai, Minit Shah, Pratik Chandrani, Anuradha Choughule, Venkataramanan Ramachandran, Vanita Noronha, Kumar Prabhash, Prashant Kumar. Targeted next generation sequencing (NGS) enables identification of rare EGFR exon-20 insertion (p.H773_V774insPHPH) in lung adenocarcinoma patientMedical Reports 2023; 2: 100018 doi: 10.1016/j.hmedic.2023.100018
31
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre ExperienceClinical Cancer Investigation Journal 2022; 11(3): 25 doi: 10.51847/87N2FdDtB1
32
Dalma Udovičić-Gagula, Nejra Džananović, Mirsad Dorić. Prevalence of epidermal growth factor receptor (EGFR) mutations and correlation with histological patterns in lung adenocarcinoma in patients from Bosnia and HerzegovinaMedicinski Glasnik 2023; 21(1): 8 doi: 10.17392/1627-23
33
Yijiang Shi, Daniel Sanghoon Shin. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including ImmunotherapyBiomolecules 2023; 13(6): 984 doi: 10.3390/biom13060984
34
Julian M. Rozenberg, Gleb I. Filkov, Alexander V. Trofimenko, Evgeny A. Karpulevich, Vladimir D. Parshin, Valery V. Royuk, Marina I. Sekacheva, Mikhail O. Durymanov. Biomedical Applications of Non-Small Cell Lung Cancer SpheroidsFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.791069
35
Ameish Govindarajan. Chasing MilestonesJournal of Clinical Oncology 2023; 41(8): 1626 doi: 10.1200/JCO.22.01379
36
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, Sandra Vietti Michelina, Pietro Scaparone, Giulio Metro, Andrea De Giglio, Federica Pecci, Giuseppe Lamberti, Chiara Ambrogio, Biagio Ricciuti. Resistance to KRAS G12C Inhibition in Non-small Cell Lung CancerCurrent Oncology Reports 2023; 25(9): 1017 doi: 10.1007/s11912-023-01436-y
37
Kenneth S. Ramos, Abeer A.I. Hassanin, Yingshan Wang. Comprehensive Precision Medicine2024; : 465 doi: 10.1016/B978-0-12-824010-6.00034-4
38
Ayaka Saito, Hideki Terai, Tae‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mitsuishi, Taro Shinozaki, Keiko Ohgino, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Kawada, Kenzo Soejima, Hiroshi Nishihara, Koichi Fukunaga. Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence dataCancer Medicine 2024; 13(4) doi: 10.1002/cam4.7077
39
Rachael Batteson, Emma Hook, Hollie Wheat, Anthony J. Hatswell, Helene Vioix, Thomas McLean, Stamatia Theodora Alexopoulos, Shobhit Baijal, Paul K. Paik. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UKTargeted Oncology 2024; 19(2): 191 doi: 10.1007/s11523-024-01038-z
40
Sara Salucci, Beatrice Aramini, Anna Bartoletti-Stella, Ilaria Versari, Giovanni Martinelli, William Blalock, Franco Stella, Irene Faenza. Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic ApproachesCancers 2023; 15(12): 3245 doi: 10.3390/cancers15123245
41
Federica Cosso, Giandomenico Roviello, Martina Catalano, Cristina Botteri, Camilla Eva Comin, Francesca Castiglione, Katia Ferrari, Editta Baldini, Enrico Mini. A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coinAnti-Cancer Drugs 2024; 35(1): 76 doi: 10.1097/CAD.0000000000001517
42
Dasom Kim, Dongwha Min, Joohee Kim, Min Jung Kim, Yerim Seo, Byung Hwa Jung, Seung‑Hae Kwon, Hyunju Ro, Seoee Lee, Jason K. Sa, Ji-Yun Lee. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2Journal of Experimental & Clinical Cancer Research 2023; 42(1) doi: 10.1186/s13046-023-02922-8
43
Izzet Dogan, Nijat Khanmammadov, Anıl Yıldız, Melin Aydan Ahmed, Sezai Vatansever, Pinar Saip, Adnan Aydiner. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitorsJournal of Cancer Research and Therapeutics 2023; 19(7): 1945 doi: 10.4103/jcrt.jcrt_877_22
44
James E. Frampton. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLCTargeted Oncology 2022; 17(3): 369 doi: 10.1007/s11523-022-00883-0
45
Alessia Salzillo, Angela Ragone, Annamaria Spina, Silvio Naviglio, Luigi Sapio. Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axisEuropean Journal of Cell Biology 2023; 102(2): 151292 doi: 10.1016/j.ejcb.2023.151292
46
Jerold Loh, Yvonne Li En Ang, Amit Jain, Joe Yeong, Raghav Sundar. Targeting Anaplastic Lymphoma Kinase in GI Primary MalignanciesJCO Precision Oncology 2022; (6) doi: 10.1200/PO.22.00208
47
Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai. Targeted therapeutic options in early and metastatic NSCLC-overviewPathology and Oncology Research 2024; 30 doi: 10.3389/pore.2024.1611715
48
Simona Stefania Juncu, Anca Victorita Trifan, Horia Minea. From spotlight to shadow: ALK inhibitor-induced acute liver failure in a patient with non-small cell lung cancerArchive of Clinical Cases 2023; 10(4): 160 doi: 10.22551/2023.41.1004.10266
49
Alessia Pellerino, Tara Marie Davidson, Shreyas S. Bellur, Manmeet S. Ahluwalia, Hussein Tawbi, Roberta Rudà, Riccardo Soffietti. Prevention of Brain Metastases: A New FrontierCancers 2024; 16(11): 2134 doi: 10.3390/cancers16112134
50
Xuyang Song, Jinxi He, Bingqing Shi, Yuning Han, Yoke Keong Yong. Hypoxic Microenvironment-Induced Reduction in PTEN-L Secretion Promotes Non-Small Cell Lung Cancer Metastasis through PI3K/AKT PathwayEvidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/6683104
51
Hayoung Seong, Soo Han Kim, Mi Hyun Kim, Jeong Su Cho, Ahrong Kim, Jung Seop Eom. Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangementFrontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1343238
52
Salman Alamery, Anfal AlAjmi, Tanveer A. Wani, Seema Zargar. In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker GenesMedicina 2023; 59(11): 1923 doi: 10.3390/medicina59111923
53
Qiuqiang Chen, Gang Jia, Xilin Zhang, Wenxue Ma. Targeting HER3 to overcome EGFR TKI resistance in NSCLCFrontiers in Immunology 2024; 14 doi: 10.3389/fimmu.2023.1332057
54
Sarah J. Gao, Lan Jin, Hugh W. Meadows, Timothy D. Shafman, Cary P. Gross, James B. Yu, Hugo J.W. L. Aerts, Joseph A. Miccio, John M. Stahl, Raymond H. Mak, Roy H. Decker, Benjamin H. Kann. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional ModelJournal of Thoracic Oncology 2023; 18(3): 339 doi: 10.1016/j.jtho.2022.11.007
55
Hanwen Wang, Theinmozhi Arulraj, Holly Kimko, Aleksander S. Popel. Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibitionnpj Precision Oncology 2023; 7(1) doi: 10.1038/s41698-023-00405-9
56
Federica Pezzuto, Véronique Hofman, Christophe Bontoux, Francesco Fortarezza, Francesca Lunardi, Fiorella Calabrese, Paul Hofman. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Lung Cancer 2023; 181: 107249 doi: 10.1016/j.lungcan.2023.107249
57
Saumya D. Sisoudiya, Armande Ang Houle, Tharu Fernando, Timothy R. Wilson, Jennifer L. Schutzman, Jessica Lee, Alexa Schrock, Ethan S. Sokol, Smruthy Sivakumar, Zhen Shi, Gaurav Pathria. Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLCnpj Precision Oncology 2024; 8(1) doi: 10.1038/s41698-024-00644-4
58
A. L. Kornietskaya, L. V. Bolotina, S. F. Evdokimova, N. S. Prizova, Yu. B. Karagodina, V. V. Savchina, A. A. Fedenko. First-line treatment option for patients with ALK-positive metastatic NSCLCMeditsinskiy sovet = Medical Council 2023; (22): 74 doi: 10.21518/ms2023-434
59
Lin Li, Wencai Li, Chunyan Wu, Yanfeng Xi, Lei Guo, Yuan Ji, Lili Jiang, Ji Li, Jingping Yun, Gang Chen, Yuan Li, Yueping Liu, Dianbin Mu, Yuchen Han, Leina Sun, Qingxin Xia, Xiaodong Teng, Nanying Che, Wei Wu, Xueshan Qiu, Chao Liu, Xiaochu Yan, Daiqiang Li, Zhihong Zhang, Zhe Wang, Yujun Li, Zheng Wang, Lingchuan Guo, Xiu Nie, Jingshu Geng, Jianhua Zhou, Jianming Ying. Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective studyCancer Communications 2024;  doi: 10.1002/cac2.12593
60
Ruth Moulson, Jennifer Law, Adrian Sacher, Geoffrey Liu, Frances A. Shepherd, Penelope Bradbury, Lawson Eng, Sandra Iczkovitz, Erica Abbie, Julia Elia-Pacitti, Emmanuel M. Ewara, Viktoriia Mokriak, Jessica Weiss, Christopher Pettengell, Natasha B. Leighl. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial IntelligenceCurrent Oncology 2024; 31(4): 1947 doi: 10.3390/curroncol31040146
61
Pratik Mohanty, Babita Pande, Rakesh Acharya, L V K S Bhaskar, Henu Kumar Verma. Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic PathwaysDiseases 2024; 12(5): 93 doi: 10.3390/diseases12050093
62
Brandon S. Sheffield, Andrea Beharry, Joanne Diep, Kirstin Perdrizet, Marco A. J. Iafolla, William Raskin, Shaan Dudani, Mary Anne Brett, Blerta Starova, Brian Olsen, Parneet K. Cheema. Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer CareCurrent Oncology 2022; 29(3): 1326 doi: 10.3390/curroncol29030113
63
Guowei Gong, Kumar Ganesan, Qingping Xiong, Yuzhong Zheng, Daniel Dias Rufino Arcanjo. Antitumor Effects of Ononin by Modulation of Apoptosis in Non-Small-Cell Lung Cancer through Inhibiting PI3K/Akt/mTOR PathwayOxidative Medicine and Cellular Longevity 2022; 2022: 1 doi: 10.1155/2022/5122448
64
涤非 曹. Study on Driver Genes of Non-Small Cell Lung CancerHans Journal of Biomedicine 2022; 12(01): 9 doi: 10.12677/HJBM.2022.121002
65
Cliff Molife, Katherine B. Winfree, Hollie Bailey, Yulia D’yachkova, Cameron Forshaw, Sangmi Kim, Kaisa-Leena Taipale, Tarun Puri. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World StudyAdvances in Therapy 2023; 40(7): 3135 doi: 10.1007/s12325-023-02530-0
66
Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, Claire Couty, Bastien Martin, Evgueni Jacob, Michaël Duruisseaux, Jean-Louis Palgen, Claudio Monteiro, Adèle L’Hostis. Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung AdenocarcinomaBiomedicines 2024; 12(3): 704 doi: 10.3390/biomedicines12030704
67
Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee, Raja Ganesan. Advances in the Lung Cancer Immunotherapy ApproachesVaccines 2022; 10(11): 1963 doi: 10.3390/vaccines10111963
68
Rebecca Ibrahim, Claude Chahine, Tony Felefly, Nadine Khalife, Khalil Saleh. The CLIP1 – LTK fusion: anew oncogenic driver in non-small-cell lung cancer? Future Oncology 2023; 19(4): 273 doi: 10.2217/fon-2022-1232
69
Jayson R. Nelson, Derek J. Matheson, Oluwaseun E. Omoba, Candace L. Winterton, Clayton D. Rawson, Elena M. Kurudza, Brandon P. Lucke-Wold. Interdisciplinary Cancer Research 2024;  doi: 10.1007/16833_2024_236
70
Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Takashi Nishizawa, Hironori Fukuda, Kana Ohashi, Kosuke Arai, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Toru Maruyama, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Hideaki Mizuno, Hiroyuki Tsunoda, Atsushi Ochiai. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic AlterationsCancer Research Communications 2023; 3(6): 1026 doi: 10.1158/2767-9764.CRC-22-0415
71
Bongyong Lee, Andrew Chern, Andrew Y. Fu, Aiguo Zhang, Michael Y. Sha. A Highly Sensitive XNA-Based RT-qPCR Assay for the Identification of ALK, RET, and ROS1 Fusions in Lung CancerDiagnostics 2024; 14(5): 488 doi: 10.3390/diagnostics14050488
72
Iwona Ziółkowska-Suchanek, Magdalena Żurawek. FOXP3: A Player of Immunogenetic Architecture in Lung CancerGenes 2024; 15(4): 493 doi: 10.3390/genes15040493
73
Ivan P. Gorlov, Olga Y. Gorlova, Spyridon Tsavachidis, Christopher I. Amos. Strength of selection in lung tumors correlates with clinical features better than tumor mutation burdenScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63468-z
74
Wan-Li Cheng, Po-Hao Feng, Kang-Yun Lee, Kuan-Yuan Chen, Wei-Lun Sun, Nguyen Van Hiep, Ching-Shan Luo, Sheng-Ming Wu. The Role of EREG/EGFR Pathway in Tumor ProgressionInternational Journal of Molecular Sciences 2021; 22(23): 12828 doi: 10.3390/ijms222312828
75
Xavier Baer, Mathieu Chevallier, Juliana Rey Cobo, Jérôme Plojoux, Claudio De Vito, Alfredo Addeo. Rare Synchronous Lung Cancers in a Nonsmoker with Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition Alterations: A Case ReportCase Reports in Oncology 2024; 17(1): 549 doi: 10.1159/000538019
76
Marisa L. Martin-Fernandez. Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung CancerCancers 2022; 14(3): 686 doi: 10.3390/cancers14030686
77
Geoffrey Liu, Julien Mazieres, Jan Stratmann, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J. Solomon, Todd M. Bauer. A pragmatic guide for management of adverse events associated with lorlatinibLung Cancer 2024; 191: 107535 doi: 10.1016/j.lungcan.2024.107535
78
Meifang Liu, Jie Yang, Lagen Wan, Rui Zhao. Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with ChemotherapyCancer Management and Research 2021; : 4921 doi: 10.2147/CMAR.S308659
79
Alessandro La Ferlita, Rosario Distefano, Salvatore Alaimo, Joal D. Beane, Alfredo Ferro, Carlo M. Croce, Philip N. Tsichlis, Alfredo Pulvirenti, Giovanni Nigita. Transcriptome Analysis of Human Endogenous Retroviruses at Locus-Specific Resolution in Non-Small Cell Lung CancerCancers 2022; 14(18): 4433 doi: 10.3390/cancers14184433
80
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, M. Rita Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andres Cardona, Thorsten Ruf, Johannes Noe, Benjamin J. Solomon. Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer New England Journal of Medicine 2024; 390(14): 1265 doi: 10.1056/NEJMoa2310532
81
Vikram Sumbly, Ian Landry. Unraveling the Role of STK11/LKB1 in Non-small Cell Lung CancerCureus 2022;  doi: 10.7759/cureus.21078
82
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang. Current treatments for non-small cell lung cancerFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.945102
83
Carmen María Valencia Soto, Virginia Martínez Callejo, Adela García-Avello Fernández-Cueto, María Victoria Villacañas Palomares, Sara Barbadillo Villanueva, María Ochagavía Sufrategui, Marta Francisca López-Brea Piqueras, Marta Valero Domínguez. Severe hepatotoxicity during treatment with capmatinibJournal of Oncology Pharmacy Practice 2023; 29(6): 1484 doi: 10.1177/10781552231173120
84
Kelsey S Lau-Min, Yaxin Wu, Shavon Rochester, Justin E Bekelman, Genevieve P Kanter, Kelly D Getz. Association between oral targeted cancer drug net health benefit, uptake, and spendingJNCI: Journal of the National Cancer Institute 2024;  doi: 10.1093/jnci/djae110
85
Hongyuan Liang, Lingyun Zhang, Jian Rong. Potential roles of exosomes in the initiation and metastatic progression of lung cancerBiomedicine & Pharmacotherapy 2023; 165: 115222 doi: 10.1016/j.biopha.2023.115222
86
Guiping Yu, Yiqi Chen, Yuwen Hu, Yan Zhou, Xiaoling Ding, Xiaorong Zhou. Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulationFrontiers in Cell and Developmental Biology 2022; 10 doi: 10.3389/fcell.2022.1010639
87
Kenta Ninomiya, Hidetaka Arimura, Kentaro Tanaka, Wai Yee Chan, Yutaro Kabata, Shinichi Mizuno, Nadia Fareeda Muhammad Gowdh, Nur Adura Yaakup, Chong-Kin Liam, Chee-Shee Chai, Kwan Hoong Ng. Three-dimensional topological radiogenomics of epidermal growth factor receptor Del19 and L858R mutation subtypes on computed tomography images of lung cancer patientsComputer Methods and Programs in Biomedicine 2023; 236: 107544 doi: 10.1016/j.cmpb.2023.107544
88
Urska Janzic, Walid Shalata, Katarzyna Szymczak, Rafał Dziadziuszko, Marko Jakopovic, Giannis Mountzios, Adam Płużański, Antonio Araujo, Andriani Charpidou, Abed Agbarya. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping MutationsInternational Journal of Molecular Sciences 2023; 24(16): 12840 doi: 10.3390/ijms241612840
89
Kenta Ninomiya, Hidetaka Arimura, Kentaro Tanaka, Wai Yee Chan, Yutaro Kabata, Shinichi Mizuno, Nadia Muhammad Gowdh, Nur Adura Yaakup, Chong Kin Liam, Chee-Shee Chai, Kwan Hoong Ng. Three-Dimensional Topological Radiogenomics of Epidermal Growth Factor Receptor Del19 and L858R Mutation Subtypes on Computed Tomography Images of Lung Cancer PatientsSSRN Electronic Journal 2022;  doi: 10.2139/ssrn.4093528
90
Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Masoud Ghanaatian, Fatemeh Rezaei-Tazangi, Payam Baziyar, Amirhossein Ahmadi, Michael R. Hamblin, Amir Reza Aref. Receptor tyrosine kinase inhibitors in cancerCellular and Molecular Life Sciences 2023; 80(4) doi: 10.1007/s00018-023-04729-4
91
Mina Roshan-Zamir, Aida Khademolhosseini, Kavi Rajalingam, Abbas Ghaderi, Raja Rajalingam. The genomic landscape of the immune system in lung cancer: present insights and continuing investigationsFrontiers in Genetics 2024; 15 doi: 10.3389/fgene.2024.1414487
92
Dingani Nkosi, Giby V. George, Huijie Liu, Meghan Buldo, Moises J. Velez, Zoltán N. Oltvai. Efficient Lung Cancer Molecular Diagnostics by Combining Next Generation Sequencing with Reflex Idylla Genefusion Assay TestingGenes 2023; 14(8): 1551 doi: 10.3390/genes14081551
93
Motohiro Izumi, Daniel B. Costa, Susumu S. Kobayashi. Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancerLung Cancer 2024; 194: 107885 doi: 10.1016/j.lungcan.2024.107885
94
Emma Loeffler, Julien Ancel, Véronique Dalstein, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic StrategiesLife 2023; 14(1): 64 doi: 10.3390/life14010064
95
S. Shukla, A. Karbhari, S. Rastogi, U. Agarwal, P. Rai, A. Mahajan. Bench-to-bedside imaging in brain metastases: a road to precision oncologyClinical Radiology 2024; 79(7): 485 doi: 10.1016/j.crad.2024.02.015
96
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz. Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies EraInternational Journal of Molecular Sciences 2022; 23(12): 6477 doi: 10.3390/ijms23126477
97
Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi, Judit Moldvay. PD-1 and PD-L1 expression in rare lung tumorsPathology and Oncology Research 2023; 29 doi: 10.3389/pore.2023.1611164
98
Anggraeni E. Kusumaningrum, Sarce Makaba, Eyhab Ali, Mandeep Singh, Mohammed N. Fenjan, Irodakhon Rasulova, Neeti Misra, Sada G. Al‐ Musawi, Ali Alsalamy. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceCell Biochemistry and Function 2024; 42(1) doi: 10.1002/cbf.3906